Why did the company that made a brand new antibiotic go bankrupt right after getting it approved, and what does that mean for whether we'll have new drugs in the future?

Question

Accepted Answer

**The brutal answer: Achaogen did almost everything society says it wants — developed a new antibiotic, got FDA approval for plazomicin in June 2018, aimed it at dangerous resistant infections — and then filed for bankruptcy in April 2019 because the drug could not generate enough sales.** The hidden trap is that a good new antibiotic is supposed to be *held in reserve*, not sold widely. Stewardship protects the drug medically but destroys the normal pharmaceutical business model financially.

Here’s the paradox.

A cancer drug or diabetes drug succeeds by being used as much as possible in eligible patients. A new antibiotic succeeds clinically by being used as little as possible — saved for resistant infections, guided by susceptibility testing, restricted by hospital stewardship teams, and often replaced by older cheaper drugs when those still work.

Achaogen’s plazomicin hit that wall.

### Why Achaogen collapsed after approval

1. **The target population was tiny and hard to treat**
   Plazomicin was designed for serious resistant Gram-negative infections, including carbapenem-resistant Enterobacteriaceae. These are high-stakes infections, but not a mass market.

2. **The clinical trial economics were punishing**
   Achaogen’s trial against carbapenem-resistant Enterobacteriaceae screened about **2,000 patients** but enrolled only **39**, with an estimated cost of roughly **$1 million per recruited patient**. That is a nightmare for any company trying to prove value in rare, resistant infections.

3. **Hospitals were cautious**
   Antibiotic stewardship programs encourage doctors to use the right drug, dose, and duration — and to reserve newer agents when possible. That is medically correct. But for Achaogen, it meant low volume.

4. **New antibiotics compete against cheap generics**
   Even when a new antibiotic is valuable, hospitals often start with older, inexpensive agents unless resistance forces escalation. A life-saving “backup” drug may sit on the shelf — exactly where public health wants it.

5. **Approval did not equal commercial survival**
   The company received FDA approval in 2018. Less than a year later, it entered bankruptcy. The lesson was chilling: regulatory success was not enough to keep an antibiotic company alive.

### This was not an isolated failure

Achaogen became the warning flare, but not the only one.

- **Melinta** filed for Chapter 11 bankruptcy in December 2019 after cutting most R&D staff in 2018.  
- **Tetraphase** was acquired by La Jolla Pharmaceuticals in 2020 for **$43 million**, far below its earlier **$1.9 billion** market cap peak.  
- **Entasis**, spun out of AstraZeneca’s antibiotic assets, raised **$75 million** in a 2018 IPO but dropped **29% on debut**, then was acquired by Innoviva in 2022 at **$2.20 per share**.  
- **Destiny Pharma** appointed administrators in 2024 after **27 years of R&D**.  
- Large companies also retreated: Merck shuttered Cubist’s antibiotic R&D unit; Sanofi transferred infectious disease R&D to Evotec; GSK shifted focus away from some antibiotic work.

The pattern is clear: the antibiotic market punishes the very restraint that public health requires.

### What it means for future antibiotics

It means we cannot rely on the normal “sell more, earn more” drug model to deliver new antibiotics.

Antimicrobial resistance is projected to cause up to **10 million deaths annually by 2050** if unchecked, yet the companies trying to make the drugs needed for that future face weak revenue, expensive trials, stewardship restrictions, and rapid investor flight.

So the future depends on changing the reward system.

### The approaches now collide

**The stewardship approach says:**  
Use antibiotics sparingly. Hospitals should run programs with leadership commitment, accountability, pharmacy expertise, tracking, reporting, education, rapid diagnostics, and post-prescription review within **48–72 hours**. This protects patients and slows resistance.

**The broken-market approach says:**  
If society wants reserve antibiotics to exist, it cannot pay companies only by pill volume. New antibiotics need “delinked” incentives — payment for availability, insurance value, and resistance preparedness, not just sales.

**The monitoring approach says:**  
Use local resistance data, prescribing dashboards, antibiograms, and audit-feedback systems so new drugs are used precisely where needed — not overused, but not ignored when they can save lives.

### The real takeaway

Achaogen did not fail because antibiotics are unimportant. It failed because antibiotics are *too important to sell like ordinary drugs*.

If nothing changes, we will keep asking companies to build fire extinguishers, then bankrupting them because we hope the extinguishers are rarely used. The future of new antibiotics depends on whether governments and health systems are willing to pay for readiness — not just consumption.

Antibiotic Stewardship: Prescribing, Education, and Market Reform

About this Capsule

8 Approaches to Antibiotic Resistance Challenges

Generic AI vs This Capsule

Why did it go bankrupt after approval?

1. New antibiotics are intentionally used sparingly

Tags

Related in Health

The Sleeper's Guide to Light, Body Clocks, and Metabolic Health

A Patient's Guide to Sleep Disorder Red Flags and Treatment Risks

A Patient's Playbook to Disputing Medical Bills

The Insomniac's Playbook for Sleepless Nights